Loading...

GRCE GRACE THERAPEUTICS INC Product Launches 8-K Filing

GRC

GRC

GRACE THERAPEUTICS INC

(GRCE)

2025 8-K

Financial Results Update

Funding Secured

Stockholder Meeting Results

FDA Drug Application

Financial Statements

Corporate Update

Financial Results

Private Placement Offering

Financial Results

Corporate Restructuring

Annual Meeting Results

Trial Enrollment Complete

CEO Employment Agreement

Earnings Reports

Phase 3 Safety Trial Enroll...

Financial Results Announcement

Regulation FD Disclosure

Earnings Report

Appointment of Robert J. De...

Dismissal of Ernst & Young ...

Settlement Agreement and Cl...

Annual Meeting of Shareholders

Private Placement Offering

Financial Results Announcement

Financial Results Announcement

Appointments and Terminations

Appointment of CEO

Resignation of Director

Dismissal of KPMG and Engag...

Earnings Reports

Compliance Extension

External Links:

Grace Therapeutics, Inc. announced that on August 22, 2025, the FDA accepted its New Drug Application for GTx-104, which is aimed at treating patients with aneurysmal subarachnoid hemorrhage, with a review target date set for April 23, 2026.

AI Assistant

GRACE THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.